Structure-based design and optimization of antihypertensive peptides to obtain high inhibitory potency against both renin and angiotensin I-converting enzyme

SAR and QSAR in Environmental Research

Volumn 26, Issue 12, 2015, Pages 1001-1016

  Zhou, Z ^a   Cheng, C ^b   Li, Y ^b  

^a Jiujiang No 1 People's Hospital   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

angiotensin I converting enzyme; cardiovascular disease; hypertension; peptide; quantitative structure activity relationship; renin

Indexed keywords

BINDING ENERGY; BIOACTIVITY; BLOOD PRESSURE; COMPUTATIONAL CHEMISTRY; ENZYMES; FREE ENERGY; MOLECULAR DYNAMICS;

ANGIOTENSIN I-CONVERTING ENZYME; ANTIHYPERTENSIVE PEPTIDES; CARDIOVASCULAR DISEASE; DESIGN AND OPTIMIZATION; HYPERTENSION; KEY ENZYMES; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; RENIN; RENIN-ANGIOTENSIN SYSTEM; STRUCTURE-BASED DESIGNS;

PEPTIDES;

EID: 84949531115     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2015.1104725     Document Type: Article

References (31)

1. P.M.Kearney, M.Whelton, K.Reynolds, P.Muntner, P.K.Whelton, and J.He, Global burden of hypertension: Analysis of worldwide data, Lancet 365 (2005), pp. 217–223.
2. J.M.Flack, R.Peters, T.Shafi, H.Alrefai, S.A.Nasser, and E.Crook, Prevention of hypertension and its complications: Theoretical basis and guidelines for treatment, J. Am. Soc. Nephrol. 14 (2003), pp. S92–S98.
3. W.C.Cushman, The burden of uncontrolled hypertension: Morbidity and mortality associated with disease progression, J. Clin. Hypertens. 5 (2003), pp. 14–22.
4. T.Gerhard, J.A.Delaney, R.M.Cooper-Dehoff, J.Shuster, B.A.Brumback, J.A.Johnson, C.J.Pepine, and A.G.Winterstein, Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy, BMC Med. Res. Methodol. 12 (2012), p. 119.
5. S.Reissmann, M.P.Filatova, N.A.Krit, and H.Feist, Peptide inhibitors of the renin-angiotensin system. 2. Polymer-bound tri-, penta- and nonapeptide inhibitors of angiotensin converting enzyme, Pharmazie 47 (1992), pp. 498–501.
6. S.A.Atlas, The renin–angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition, J. Manag. Care Pharm. 13 (2007), pp. 9–20.
7. P.Vanhee, A.M.van der Sloot, E.Verschueren, L.Serrano, F.Rousseau, and J.Schymkowitz, Computational design of peptide ligands, Trends Biotechnol. 29 (2011), pp. 231–239.
8. H.M.Berman, J.Westbrook, Z.Feng, G.Gilliland, T.N.Bhat, H.Weissig, I.N.Shindyalov, and P.E.Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242.
9. G.Masuyer, S.L.Schwager, E.D.Sturrock, R.E.Isaac, and K.R.Acharya, Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides, Sci. Rep. 2 (2012), p. 717.
10. T.Jing, J.Feng, D.Li, J.Liu, and G.He, Rational design of angiotensin-I-converting enzyme inhibitory peptides by integrating in silico modeling and an in vitro assay, ChemMedChem 8 (2013), pp. 1057–1066.
11. G.G.Krivov, M.V.Shapovalov, and R.L.Dunbrack, Improved prediction of protein side-chain conformations with SCWRL4, Proteins 77 (2009), pp. 778–795.
12. B.Knapp, U.Omasits, and W.Schreiner, Side chain substitution benchmark for peptide/MHC interaction, Protein Sci. 17 (2008), pp. 977–982.
13. Y.Ren, Q.Wang, S.Chen, and H.Cao, Integrating computational modeling and experimental assay to discover new potent ACE-inhibitory peptides, Mol. Inf. 32 (2013), pp. 1–10.
14. S.Hellberg, M.Sjoestroem, B.Skagerberg, and S.Wold, Peptide quantitative structure-activity relationships, a multivariate approach, J. Med. Chem. 30 (1987), pp. 1126–1135.
15. J.H.Wang, Y.L.Liu, J.H.Ning, J.Yu, X.H.Li, and F.X.Wang, Is the structural diversity of tripeptides sufficient for developing functional food additives with satisfactory multiple bioactivities, J. Mol. Struct. 2013 (1040), pp. 164–170.
16. S.Wold, M.Sjotrom, and L.Eriksson, PLS-regression: A basic tool of chemometrics, Chemom. Intel. Lab. Syst. 58 (2001), pp. 109–130.
17. M.Karplus and J.A.McCammon, Molecular dynamics simulations of biomolecules, Nat. Struct. Biol. 9 (2002), pp. 646–652.
18. W.L.Jorgensen, J.Chandrasekhar, J.D.Madura, R.W.Impey, and M.L.Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79 (1983), pp. 926–935.
19. Y.Duan, C.Wu, S.Chowdhury, M.C.Lee, G.Xiong, W.Zhang, R.Yang, P.Cieplak, R.Luo, T.Lee, J.Caldwell, J.Wang, and P.Kollman, A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations, J. Comput. Chem. 24 (2003), pp. 1999–2012.
20. J.Ryckaert, G.Ciccotti, and H.J.C.Berendsen, Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes, J. Comput. Phys. 23 (1977), pp. 327–341.
21. N.Homeyer and H.Gohlke, Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method, Mol. Inf. 31 (2012), pp. 114–122.
22. D.A.Case, T.E.Cheatham, T.Darden, H.Gohlke, R.Luo, K.M.Merz, A.Onufriev, C.Simmerling, B.Wang, and R.J.Woods, The Amber biomolecular simulation programs, J. Comput. Chem. 26 (2005), pp. 1668–1688.
23. C.C.Udenigwe, H.Li, and R.E.Aluko, Quantitative structure–activity relationship modeling of renin-inhibiting dipeptides, Amino Acids 42 (2012), pp. 1379–1386.
24. B.Hernandez-Ledesma, L.Amigo, I.Recio, and B.Bartolome, ACE-inhibitory and radical-scavenging activity of peptides derived from beta-lactoglobulin f(19–25). Interactions with ascorbic acid, J. Agric. Food Chem. 55 (2007), pp. 3392–3397.
25. A.C.Wallace, P.A.Laskowski, and J.M.Thornton, LIGPLOT: A program to generate schematic diagrams of protein–ligand interactions, Protein Eng. 8 (1995), pp. 127–134.
26. P.Zhou, J.Huang, and F.Tian, Specific noncovalent interactions at protein–ligand interface: Implications for rational drug design, Curr. Med. Chem. 19 (2012), pp. 226–238.
27. T.Kortemme, D.E.Kim, and D.Baker, Computational alanine scanning of protein–protein interfaces, Sci. STKE 2004 (2004), p. pl2.
28. Z.Zhou, Y.Wang, and S.H.Bryant, QSAR models for predicting cathepsin B inhibition by small molecules – continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules, J. Mol. Graph. Model. 28 (2010), pp. 714–727.
29. J.S.Kang, S.Kang, D.Y.Ryu, Y.S.Lee, J.K.Lee, T.S.Kang, H.J.Park, and S.Yoon, Comparative study of active and inactive hepatocarcinogens using a QSAR-based prediction model, Mol. Cell. Toxicol. 8 (2012), pp. 383–391.
30. A.Golbraikh and A.Tropsha, Beware of q2, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
31. R.He, R.E.Aluko, and X.R.Ju, Evaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzyme, PLoS ONE 9 (2014), p. e91051.